Glaxosmithkline Plc (GSK) Stock Value Rose While Camelot Portfolios Lowered Stake; Cognizant Tech Solutns Cl A (CTSH) Holder Reinhart Partners Lowered Its Position as Market Value Declined

June 14, 2018 - By Migdalia James

GlaxoSmithKline plc (NYSE:GSK) Logo

Camelot Portfolios Llc decreased its stake in Glaxosmithkline Plc (GSK) by 61.07% based on its latest 2018Q1 regulatory filing with the SEC. Camelot Portfolios Llc sold 12,698 shares as the company’s stock rose 7.70% while stock markets declined. The institutional investor held 8,093 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $801,000, down from 20,791 at the end of the previous reported quarter. Camelot Portfolios Llc who had been investing in Glaxosmithkline Plc for a number of months, seems to be less bullish one the $103.56B market cap company. The stock increased 1.94% or $0.8 during the last trading session, reaching $41.94. About 3.50 million shares traded or 26.55% up from the average. GlaxoSmithKline plc (NYSE:GSK) has declined 6.39% since June 14, 2017 and is downtrending. It has underperformed by 18.96% the S&P500. Some Historical GSK News: 24/05/2018 – Animal Health: Danone, Nestle, KKR and more suit up for GSK consumer bidding war: report; 12/04/2018 – Top 3 stories today — #1 not a buyer, but a taker UPDATED: Continuing an R&D revamp, GlaxoSmithKline hands off its rare disease unit to Orchard Therapeutics $GSK; 29/05/2018 – GSK SUBMITS REGULATORY APPLICATION IN JAPAN FOR ONCE-DAILY SINGLE INHALER TRIPLE THERAPY FF/UMEC/Vl FOR PATIENTS WITH COPD; 11/05/2018 – GSK CONSUMER 4Q REV. 11.8B RUPEES; 12/04/2018 – GlaxoSmithKline Takes 19.9% Stake in Orchard Therapeutics; 11/04/2018 – GSK’S OUTLOOK TO NEGATIVE FROM STABLE BY FITCH; 24/05/2018 – GSK PHARMA INDIA 4Q REV. 7.49B RUPEES, EST. 7.84B; 27/03/2018 – Novartis Selling Consumer-healthcare JV Stake To GlaxoSmithKline — MarketWatch; 24/04/2018 – GlaxoSmithKline and Innoviva: Boxed Warning Has Also Been Removed From Trelegy Ellipta Prescribing Information; 16/03/2018 – CVS to offer GSK’s new shingles vaccine at stores nationwide

Reinhart Partners Inc decreased its stake in Cognizant Tech Solutns Cl A (CTSH) by 2.73% based on its latest 2018Q1 regulatory filing with the SEC. Reinhart Partners Inc sold 7,335 shares as the company’s stock declined 8.67% with the market. The institutional investor held 261,610 shares of the edp services company at the end of 2018Q1, valued at $21.06M, down from 268,945 at the end of the previous reported quarter. Reinhart Partners Inc who had been investing in Cognizant Tech Solutns Cl A for a number of months, seems to be less bullish one the $46.02 billion market cap company. The stock increased 0.68% or $0.53 during the last trading session, reaching $78.55. About 3.10 million shares traded. Cognizant Technology Solutions Corporation (NASDAQ:CTSH) has risen 13.31% since June 14, 2017 and is uptrending. It has outperformed by 0.74% the S&P500.

More notable recent GlaxoSmithKline plc (NYSE:GSK) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: FDA Nods For Teligent And Keytruda, Sonoma’s Q4 Miss, Sage Inks Deal With Japan’s …” on June 14, 2018, also Streetinsider.com with their article: “European shares rally after ECB pushes back rate hike bets” published on June 14, 2018, Benzinga.com published: “31 Stocks Moving In Thursday’s Mid-Day Session” on June 14, 2018. More interesting news about GlaxoSmithKline plc (NYSE:GSK) were released by: Fool.com and their article: “Is GlaxoSmithKline plc Stock a Buy?” published on May 31, 2018 as well as Bizjournals.com‘s news article titled: “In quest to leapfrog Pfizer, Peninsula vaccine company gets $85 million injection” with publication date: June 07, 2018.

Camelot Portfolios Llc, which manages about $349.26M and $214.41M US Long portfolio, upped its stake in Walmart Inc (NYSE:WMT) by 5,324 shares to 7,505 shares, valued at $668,000 in 2018Q1, according to the filing. It also increased its holding in First Tr Lrge Cp Core Alpha (FEX) by 11,751 shares in the quarter, for a total of 19,956 shares, and has risen its stake in Ares Cap Corp (NASDAQ:ARCC).

Among 18 analysts covering GlaxoSmithKline (NYSE:GSK), 9 have Buy rating, 1 Sell and 8 Hold. Therefore 50% are positive. GlaxoSmithKline had 29 analyst reports since September 8, 2015 according to SRatingsIntel. The stock has “Neutral” rating by J P Morgan Chase Co on Friday, June 16. The company was upgraded on Tuesday, September 8 by Bank of America. The stock of GlaxoSmithKline plc (NYSE:GSK) has “Underweight” rating given on Friday, September 8 by Morgan Stanley. As per Monday, October 12, the company rating was upgraded by JP Morgan. The company was downgraded on Wednesday, September 14 by BNP Paribas. The stock of GlaxoSmithKline plc (NYSE:GSK) has “Neutral” rating given on Wednesday, April 26 by JP Morgan. The firm has “Buy” rating by Bank of America given on Wednesday, December 9. Berenberg upgraded GlaxoSmithKline plc (NYSE:GSK) on Friday, May 26 to “Buy” rating. The firm earned “Buy” rating on Tuesday, January 16 by Barclays Capital. The firm earned “Buy” rating on Monday, November 27 by UBS.

Analysts await GlaxoSmithKline plc (NYSE:GSK) to report earnings on July, 25. They expect $0.78 EPS, up 11.43% or $0.08 from last year’s $0.7 per share. GSK’s profit will be $1.93B for 13.44 P/E if the $0.78 EPS becomes a reality. After $0.68 actual EPS reported by GlaxoSmithKline plc for the previous quarter, Wall Street now forecasts 14.71% EPS growth.

More important recent Cognizant Technology Solutions Corporation (NASDAQ:CTSH) news were published by: Prnewswire.com which released: “Cognizant’s Netcentric Named 2018 Adobe Experience Cloud Partner of the Year in EMEA” on June 14, 2018, also Seekingalpha.com published article titled: “STMicroelectronics Is Inexpensive – Cramer’s Lightning Round (6/1/18)”, Streetinsider.com published: “Cognizant (CTSH) Announces CEO Francisco D’Souza as New Board Vice Chairman” on June 13, 2018. More interesting news about Cognizant Technology Solutions Corporation (NASDAQ:CTSH) was released by: Prnewswire.com and their article: “Australian Utility Endeavour Energy chooses Cognizant for their Digital Transformation” with publication date: June 06, 2018.

Investors sentiment decreased to 0.97 in Q1 2018. Its down 0.22, from 1.19 in 2017Q4. It fall, as 44 investors sold CTSH shares while 338 reduced holdings. 100 funds opened positions while 269 raised stakes. 491.22 million shares or 0.15% less from 491.94 million shares in 2017Q4 were reported. Rothschild Investment Il holds 2,527 shares or 0.03% of its portfolio. Altrinsic Glob Advisors Ltd reported 405,192 shares or 1.32% of all its holdings. Daiwa Secs Gru owns 114,034 shares. Eulav Asset has 34,000 shares. Pnc Financial Svcs Incorporated invested in 0.03% or 416,097 shares. Hm Payson has 0.03% invested in Cognizant Technology Solutions Corporation (NASDAQ:CTSH). Fort Washington Inc Oh stated it has 203,475 shares. Glenmede Tru Na invested in 0.72% or 2.44M shares. 5,896 are owned by Gofen & Glossberg Limited Liability Corp Il. Nelson Van Denburg Campbell Wealth Mgmt Group Inc Inc Ltd Llc invested in 3,678 shares. Schwab Charles Management Inc stated it has 0.14% of its portfolio in Cognizant Technology Solutions Corporation (NASDAQ:CTSH). Alliancebernstein Limited Partnership reported 5.69M shares stake. 1832 Asset Management Lp has 0.45% invested in Cognizant Technology Solutions Corporation (NASDAQ:CTSH) for 1.50M shares. Amf Pensionsforsakring Ab accumulated 0.64% or 763,499 shares. Acadian Asset Ltd Limited Liability Company invested 0.06% of its portfolio in Cognizant Technology Solutions Corporation (NASDAQ:CTSH).

Among 33 analysts covering Cognizant Technology Solutions Corp. (NASDAQ:CTSH), 26 have Buy rating, 1 Sell and 6 Hold. Therefore 79% are positive. Cognizant Technology Solutions Corp. had 92 analyst reports since August 6, 2015 according to SRatingsIntel. Monness Crespi & Hardt maintained the stock with “Buy” rating in Thursday, November 5 report. The rating was upgraded by Argus Research on Thursday, February 22 to “Buy”. The firm earned “Buy” rating on Thursday, November 9 by RBC Capital Markets. The firm has “Buy” rating by RBC Capital Markets given on Friday, October 6. Berenberg upgraded Cognizant Technology Solutions Corporation (NASDAQ:CTSH) on Tuesday, August 8 to “Buy” rating. Needham maintained Cognizant Technology Solutions Corporation (NASDAQ:CTSH) rating on Tuesday, November 8. Needham has “Buy” rating and $65 target. Bank of America maintained it with “Buy” rating and $89 target in Thursday, February 8 report. Cowen & Co maintained the shares of CTSH in report on Wednesday, September 6 with “Buy” rating. RBC Capital Markets maintained the stock with “Buy” rating in Tuesday, September 5 report. On Thursday, June 8 the stock rating was downgraded by HSBC to “Hold”.

Reinhart Partners Inc, which manages about $4.85B and $970.69M US Long portfolio, upped its stake in Alexander & Baldwin In Com (NYSE:ALEX) by 78,719 shares to 152,919 shares, valued at $3.54M in 2018Q1, according to the filing. It also increased its holding in Amerco Com (NASDAQ:UHAL) by 23,103 shares in the quarter, for a total of 86,513 shares, and has risen its stake in Ugi Corp (NYSE:UGI).

Cognizant Technology Solutions Corporation (NASDAQ:CTSH) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Migdalia James

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:








Recent Posts